Jump to content

PEAQX: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
PrimeBOT (talk | contribs)
Bots
2,048,701 edits
m →top: convert deprecated magic links to template usage, update CS1 params in templates - BRFA
 
(11 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
Line 4: Line 5:
| verifiedrevid = 429827414
| verifiedrevid = 429827414
| IUPAC_name = ({[(1S)-1-(4-bromophenyl)ethyl]amino}-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl)phosphonic acid
| IUPAC_name = ({[(1S)-1-(4-bromophenyl)ethyl]amino}-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl)phosphonic acid
| image = PEAQX.png
| image = PEAQX.svg
| width = 240
| width = 240


Line 17: Line 18:
| legal_US =
| legal_US =
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
Line 24: Line 25:
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number =
| CAS_number = 459836-30-7
| ATC_prefix =
| ATC_prefix =
| ATC_suffix =
| ATC_suffix =
Line 34: Line 35:
| ChemSpiderID = 8044242
| ChemSpiderID = 8044242
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LE8K7M4APN
| ChEMBL = 273636


<!--Chemical data-->
<!--Chemical data-->
| C=17 | H=17 | Br=1 | N=3 | O=5 | P=1
| C=17 | H=17 | Br=1 | N=3 | O=5 | P=1
| molecular_weight = 454.211 g/mol
| synonyms = PEAQX, NVP-AAM077
| synonyms = PEAQX, NVP-AAM077
| smiles = C[C@@H](C1=CC=C(C=C1)Br)NC(C2=C3C(=CC=C2)N=C(C(=N3)O)O)P(=O)(O)O
| smiles = C[C@@H](C1=CC=C(C=C1)Br)NC(C2=C3C(=CC=C2)N=C(C(=N3)O)O)P(=O)(O)O
Line 45: Line 48:
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = XXZGNAZRWCBSBK-WFVOFKTRSA-N
| StdInChIKey = XXZGNAZRWCBSBK-WFVOFKTRSA-N

}}
}}


'''PEAQX''' is a competitive [[antagonist (pharmacology)|antagonist]] at the [[NMDA receptor]]. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies<ref>Frizelle PA, Chen PE, Wyllie DJ Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission. ''Molecular Pharmacology'' 2006 Sep;70(3):1022-32. {{PMID|16778008}}</ref> of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent [[anticonvulsant]] in animal tests.<ref>Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. ''Bioorganic and Medicinal Chemistry Letters''. 2002 Apr 8;12(7):1099-102. {{PMID|11909726}}</ref>
'''PEAQX''' is a competitive [[antagonist (pharmacology)|antagonist]] at the [[NMDA receptor]]. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies<ref>{{cite journal | vauthors = Frizelle PA, Chen PE, Wyllie DJ | title = Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission | journal = Molecular Pharmacology | volume = 70 | issue = 3 | pages = 1022–32 | date = September 2006 | pmid = 16778008 | doi = 10.1124/mol.106.024042 | s2cid = 14304805 }}</ref> of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent [[anticonvulsant]] in animal tests.<ref>{{cite journal | vauthors = Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M | title = 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition | journal = Bioorganic & Medicinal Chemistry Letters | volume = 12 | issue = 7 | pages = 1099–102 | date = April 2002 | pmid = 11909726 | doi = 10.1016/s0960-894x(02)00074-4 }}</ref>


⚫
==References==
<references/>


⚫
== References ==
{{Glutamate_receptor_ligands}}
{{reflist}}


{{Ionotropic glutamate receptor modulators}}


[[Category:NMDA receptor antagonists]]
[[Category:NMDA receptor antagonists]]
[[Category:Organobromides]]
[[Category:4-Bromophenyl compounds]]
[[Category:Quinoxalines]]
[[Category:Quinoxalines]]
[[Category:Lactams]]
[[Category:Lactams]]
[[Category:Phosphonic acids]]

Latest revision as of 05:29, 23 September 2024

PEAQX
Clinical data
Other namesPEAQX, NVP-AAM077
Identifiers
  • ({[(1S)-1-(4-bromophenyl)ethyl]amino}-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl)phosphonic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC17H17BrN3O5P
Molar mass454.217 g·mol−1
3D model (JSmol)
  • C[C@@H](C1=CC=C(C=C1)Br)NC(C2=C3C(=CC=C2)N=C(C(=N3)O)O)P(=O)(O)O
  • InChI=1S/C17H17BrN3O5P/c1-9(10-5-7-11(18)8-6-10)19-17(27(24,25)26)12-3-2-4-13-14(12)21-16(23)15(22)20-13/h2-9,17,19H,1H3,(H,20,22)(H,21,23)(H2,24,25,26)/t9-,17?/m0/s1 ☒N
  • Key:XXZGNAZRWCBSBK-WFVOFKTRSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

PEAQX is a competitive antagonist at the NMDA receptor. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies[1] of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent anticonvulsant in animal tests.[2]

References

[edit]
  1. ^ Frizelle PA, Chen PE, Wyllie DJ (September 2006). "Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission". Molecular Pharmacology. 70 (3): 1022–32. doi:10.1124/mol.106.024042. PMID 16778008. S2CID 14304805.
  2. ^ Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M (April 2002). "5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition". Bioorganic & Medicinal Chemistry Letters. 12 (7): 1099–102. doi:10.1016/s0960-894x(02)00074-4. PMID 11909726.
Retrieved from "https://en.wikipedia.org/w/index.php?title=PEAQX&oldid=1247180637"